UCB SA (Belgium) Executives
| UCB Stock | EUR 180.00 5.85 3.36% |
UCB SA employs about 8.6 K people. The company is managed by 9 executives with a total tenure of roughly 32 years, averaging almost 3.0 years of service per executive, having 955.56 employees per reported executive. Discussion of UCB SA's management performance can provide insight into the enterprise performance.
| JeanChristophe Tellier Chairman Chairman of the Executive Committee, CEO |
| Emmanuel Caeymaex President Executive Vice President Immunology - Patient Value Unit Head |
UCB |
UCB SA Management Team Effectiveness
The company has return on total asset (ROA) of 0.0468 % which means that it generated a profit of $0.0468 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1069 %, meaning that it generated $0.1069 on every $100 dollars invested by stockholders. UCB SA's management efficiency ratios could be used to measure how well UCB SA manages its routine affairs as well as how well it operates its assets and liabilities.UCB SA Workforce Comparison
UCB SA is rated first in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 63,318. UCB SA retains roughly 8,600 in number of employees claiming about 14% of equities under Health Care industry.
The company has Profit Margin (PM) of 0.15 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.19 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.19. UCB SA Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. UCB SA Price Series Summation is a cross summation of UCB SA price series and its benchmark/peer.
UCB SA Notable Stakeholders
An UCB SA stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as UCB SA often face trade-offs trying to please all of them. UCB SA's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting UCB SA's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| JeanChristophe Tellier | Chairman of the Executive Committee, CEO | Profile | |
| Emmanuel Caeymaex | Executive Vice President Immunology - Patient Value Unit Head | Profile | |
| Charl Zyl | Executive Vice President Head of Patient Value Operations, Member of the Executive Committee | Profile | |
| JeanLuc Fleurial | Executive Vice President Chief Talent Officer, Member of the Executive Committee | Profile | |
| Sandrine CFA | Ex CFO | Profile | |
| William Silbey | Exec Counsel | Profile | |
| Pr LowFriedrich | Chief VP | Profile | |
| Kirsten LundJurgensen | Ex Solutions | Profile | |
| Caroline Vancoillie | Chief Functions | Profile |
About UCB SA Management Performance
The success or failure of an entity such as UCB SA often depends on how effective the management is. UCB SA management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of UCB management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the UCB management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
UCB SA, a biopharmaceutical company, researches, develops, manufactures, sells, and distributes biopharmaceutical solutions for people living with neurology and immunology conditions. The company was founded in 1928 and is headquartered in Brussels, Belgium. UCB SA operates under Biotechnology classification in Belgium and is traded on Brussels Stock Exchange. It employs 6828 people.
UCB SA Workforce Analysis
Traditionally, organizations such as UCB SA use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare UCB SA within its industry.UCB SA Manpower Efficiency
Return on UCB SA Manpower
| Revenue Per Employee | 671.7K | |
| Revenue Per Executive | 641.9M | |
| Net Income Per Employee | 123K | |
| Net Income Per Executive | 117.6M |
Additional Tools for UCB Stock Analysis
When running UCB SA's price analysis, check to measure UCB SA's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy UCB SA is operating at the current time. Most of UCB SA's value examination focuses on studying past and present price action to predict the probability of UCB SA's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move UCB SA's price. Additionally, you may evaluate how the addition of UCB SA to your portfolios can decrease your overall portfolio volatility.